Month 0 | Month 1 | Month 7 | Month 13 | Month 24 | |
Control | |||||
Baseline (mean) | 763.3 | ||||
95% CI | 687.4 to 839.3 | ||||
Change from month 1 | −493.9 | −470.7 | −494.6 | ||
95% CI | −581.1 to −406.58 | −557.9 to −383.38 | −581.9 to −407.34 | ||
P value | <0.0001 | <0.0001 | <0.0001 | ||
Functioning L-CRA | |||||
Baseline (mean) | 700.6 | ||||
95% CI | 637.9 to 763.3 | ||||
P value* | 0.20 | ||||
Change from month 1 | −340.9 | −325.5 | −365.1 | ||
95% CI | −436.8 to −244.93 | −421.4 to −229.56 | −461.0 to −269.14 | ||
P value | <0.0001 | <0.0001 | <0.0001 | ||
Difference cf control | −208.0 | −55.0 | −62.8 | −78.5 | |
95% CI | −314.4 to −101.56 | −161.5 to 51.42 | −169.3 to 43.59 | −184.9 to 27.97 | |
P value | <0.0001 | 0.31 | 0.25 | 0.15 | |
Non-functioning L-CRA | |||||
Baseline (mean) | 774.6 | ||||
95% CI | 605.7 to 943.5 | ||||
P value* | 0.88 | ||||
Change from month 1 | −602.8 | −574.2 | −388.4 | ||
95% CI | −813.0 to −392.60 | −784.4 to −364.00 | −598.6 to −178.20 | ||
P value | <0.0001 | <0.0001 | 0.0004 | ||
Difference cf control | −17.9 | −126.8 | −121.4 | 88.3 | |
95% CI | −203.6 to 167.85 | −312.5 to 58.91 | −307.1 to 64.31 | −97.4 to 274.07 | |
P value | 0.85 | 0.18 | 0.20 | 0.35 |
*Two-sample t-test for difference in means (sham+ranibizumab vs L-CRA+ranibizumab (functioning and non-functioning groups)).
cf, compared with; L-CRA, laser-induced chorioretinal anastomosis.